187. ESMO Awards - Episode 7

In our final take on ESMO 2025, we talk about Genitourinary Cancers. This was a dense area with numerous trials. Today we explore distimiab vedotin in those with advanced bladder cancer, the role of combining lutetium with an ARPI in advanced prostate cancer, whether de-escalation of docetaxel in high volume prostate cancer was just as efficacious as the regular six cycles, immunotherpay plus bCG in non-muscle invasive bladder cancer, adjuvant durvalumab in renal cell caricnoma and the perioperaive role of enforumab vedotin for muscle invasive bladder cancer. We're out of breath just listing off these trials, and if this hasn't gotten you excited, then probably nothing will! See you next week, where we interview our spectacular guest Professor Jenny Seligmann, who will bring you up to date on Michael's favourite topic, colorectal cancers! Studies: IMvigor011 (NCT04660344) KEYNOTE 905/EV-303 (NCT03924895) POTOMAC (NCT03528694) ARASAFE (NCT02799602) RC48-C016 (NCT05302284) PSMAddition (NCT04720157) For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at [email protected] Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners, Pfizer and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content.